Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - crizotinibum - capsule rigide - crizotinibum 250 mg, silica colloidalis anhydrica, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 1.05 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - onkologikum - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - capsule - levodopum 50.00 mg, benserazidum 12.50 mg ut benserazidi hydrochloridum, mannitolum, cellulosum microcristallinum, talcum, povidonum k 90, magnesii stearas, kapselhülle: e 172 (nigrum), e 171, e 132, gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - morbo di parkinson, delle gambe senza riposo-syndrom - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - capsule - levodopum 100.0 mg, benserazidum 25.0 mg ut benserazidi hydrochloridum, cellulosum microcristallinum, talcum, povidonum k 90, magnesii stearas, kapselhülle: e 172 (rubrum), e 171, e 132, gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - morbo di parkinson, delle gambe senza riposo-syndrom - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - capsule - levodopum 200.0 mg, benserazidum 50.0 mg ut benserazidi hydrochloridum, cellulosum microcristallinum, talcum, povidonum k 90, magnesii stearas, kapselhülle: e 172 (rubrum), e 172 (flavum), e 171, e 132, gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - morbo di parkinson, delle gambe senza riposo-syndrom - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - mebeverini hydrochloridum - hartkapseln retardiert - mebeverini hydrochloridum 200 mg, magnesii stearas, acidi ethacrylici et methylis methacrylatis polymerisatum, talcum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, triacetinum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, e 172 (nigrum), pro capsula. - spasmolytikum - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mmpharm gmbh - panobinostatum - capsule rigide - panobinostatum 10 mg ut panobinostatii lactas anhydricus, mannitolum, cellulosum microcristallinum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 171, e 133, e 172 (flavum), drucktinte: lacca, alcohol isopropylicus, e 172 (nigrum), alcohol butylicus, propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - il trattamento del mieloma multiplo - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mmpharm gmbh - panobinostatum - capsule rigide - panobinostatum 15 mg ut panobinostatii lactas anhydricus, mannitolum, cellulosum microcristallinum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, alcohol isopropylicus, e 172 (nigrum), alcohol butylicus, propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - il trattamento del mieloma multiplo - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mmpharm gmbh - panobinostatum - capsule rigide - panobinostatum 20 mg ut panobinostatii lactas anhydricus, mannitolum, cellulosum microcristallinum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, alcohol isopropylicus, e 172 (nigrum), alcohol butylicus, propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - il trattamento del mieloma multiplo - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - linaclotidum - capsule - kapsel: linaclotidum 0.29 mg, cellulosum microcristallinum, hypromellosum, calcii chloridum dihydricum, leucinum, kapselhülle: gelatina, e 171, e 172 (rubrum), e 172 (flavum), propylenglycolum, kalii hydroxidum, lacca, ammoniae solutio concentrata, e 172 (nigrum) pro capsula. - trattamento sintomatico di moderata a grave reizkolon sindrome di stipsi negli adulti - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dutasteridum, tamsulosinum - capsule - dutasteridum 0.5 mg, tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, dutasterid-weichkapsel innerhalb der hartkapsel: propylenglycoli dicaprylocapras 299.46 mg corresp. propylenglycolum 112.8 mg, e 321, gelatina, e 171, glycerolum, triglycerida media, lecithinum ex soja q.s., tamsulosin-pellets in hartkapsel: cellulosum microcristallinum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1 cum polysorbatum 80 et natrii laurilsulfas corresp. natrium 0.09 mg, dibutylis sebacas, silica colloidalis hydrica, calcii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 171, e 172 (flavum), gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - iperplasia prostatica benigna - synthetika